A doctor and a patient talking as they walk down a clinic hallway

Medicare GLP-1 Bridge: How the $50 Copay Works in 2026


Yes, Medicare now helps pay for weight-loss GLP-1s. Since July 1, 2026, the Medicare GLP-1 Bridge lets eligible people with Part D drug coverage get Wegovy, Zepbound KwikPen or Foundayo for a flat $50 a month, and CMS has extended it through December 31, 2027. If you are on Medicare, or you help a parent who is, open enrollment (Oct 15 to Dec 7, 2026) is the moment to make sure the drug coverage needed to use it stays in place.

Key facts

What is the Medicare GLP-1 Bridge?

It is a temporary CMS demonstration, basically a test program, that covers certain GLP-1 medicines for weight management outside the normal Part D benefit. Regular Part D covers GLP-1s for uses like type 2 diabetes or sleep apnea, but weight management on its own is the gap the Bridge fills. CMS Administrator Dr. Mehmet Oz put it this way at launch: “For too long, many Americans have been unable to access these treatments because of cost.”

How it runs in practice: a single central processor (Humana, under contract with CMS) handles prior authorization, claims and pharmacy payment. Your Part D plan does not have to opt in for you to use it. CMS says manufacturers agreed to a net price of about $245 per monthly supply, and you pay the $50 copay on top of Medicare’s share.

Which drugs are covered?

As of NCOA’s August 2026 guide, three:

Ozempic and Mounjaro, the diabetes-branded versions, are not part of the Bridge. CMS has said the product list can change, so check Medicare.gov/glp1bridge for the current list. For how the two weekly shots differ, see semaglutide vs tirzepatide. For the two pills, see oral Wegovy vs Foundayo.

Who qualifies for the $50 copay?

You need to be enrolled in a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. Then the medical criteria, per NCOA:

Nobody is enrolled automatically. A provider has to submit a prior authorization to the central processor, and NCOA says the request must confirm you received lifestyle counseling.

Who usually does not qualify: people who already get a GLP-1 through their regular Part D coverage, or who are eligible for it there. If the drug is prescribed for a Part D-covered use, such as type 2 diabetes, cardiovascular risk reduction, moderate to severe sleep apnea or MASH (a fatty liver disease), it goes through Part D instead, per the Obesity Action Coalition. That is not a loss: those people already have a coverage path.

The fine print

Good deal, real limits:

What to check during open enrollment

Open enrollment runs Oct 15 to Dec 7, 2026, and changes take effect Jan 1, 2027, per Medicare.gov. The Bridge itself does not depend on which plan you pick, but it does depend on having drug coverage. The Obesity Action Coalition suggests checking:

What it means for you

This is a real win on cost: a brand-name GLP-1 now costs eligible Medicare members a flat $50 a month. If you or a parent might qualify, the next step is a licensed provider who can check the BMI and health criteria, document them, and submit the prior authorization. Medicare.gov/glp1bridge and 1-800-MEDICARE can confirm eligibility. Not on Medicare? Our GLP-1 telehealth cost guide covers the other payment paths, and how to get peptides prescribed explains the legit route for everything else. For where unapproved peptides stand, see our legal status tracker.

Sources

Educational content only, not medical advice, and not a guarantee of coverage. Program rules can change; confirm current eligibility at Medicare.gov or with a licensed provider.

← All articles